2014Chinese Journal of AsthmaRequires access

Effect of tiotropium combined with salmeterol/fluticasone propionate in patients with severe-to-very severe stable chronic obstructive pulmonary disease

Mei Jin, Jinghui Li, Jing Yin

Open publisher page 0 citations

Abstract

Objective The purpose of the study was to investigate the effect of tiotropium combined with salmeterol/fluticasone propionate in patients with severe to-very severe stable chronic obstructive pulmonary disease (COPD).Methods One hundred and two patients admitted for severe-tovery severe stable COPD from January 2008 to February 2010 were randotnly assigned to receive tiotropium alone (group A),salmeterol/fluticasone propionate (50/500 μg) alone (group B),and combination of tiotropium and salmeterol/fluticasone propionate (group C),respectively,for 6 months.All patients were assessed at months 3 and 6 for pulmonary with ventilation function,exercise tolerance and health-related quality of life.Results At both months 3 and 6,pulmonary ventilation function,exercise tolerance,and health-related quality of life were improved in all groups compared with pretreatment values.Moreover,significantly greater improvement of the three indicators was observed in group C than in groups A and B (all P <0.05).Conclusions The combination of tiotropium and salmeterol/fluticasone propionate was superior to any single-agent treatment in improving pulmonary ventilation function,exercise tolerance,and quality of life in patients with severe-to-very severe stable COPD,without additional adverse effects.Therefore,it should be encouraged in clinical practice. Key words: Chronic obstructive pulmonary disease ;  Tiotropium ;  Salmeterol/fluticasone propionate

About this research paper

What this paper is about

Objective The purpose of the study was to investigate the effect of tiotropium combined with salmeterol/fluticasone propionate in patients with severe to-very severe stable chronic obstructive pulmonary disease (COPD).Methods One hundred and two patients admitted for severe-tovery severe stable COPD from January 2008 to February 2010 were randotnly assigned to receive tiotropium alone (group A),salmeterol/fluticasone propionate (50/500 μg) alone (group B),and combination of tiotropium and salmeterol/fluticasone propionate (group C),respectively,for 6 months.All patients were assessed at months 3 and 6 for pulmonary with ventilation function,exercise tolerance and health-related quality of life.Results At both months 3 and 6,pulmonary ventilation function,exercise tolerance,and health-related quality of life were improved in all groups compared with pretreatment values.Moreover,significantly greater improvement of the three indicators was observed in group C than in groups A and B (all P <0.05).Conclusions The combination of tiotropium and salmeterol/fluticasone propionate was superior to any single-agent treatment in improving pulmonary ventilation function,exercise tolerance,and quality of life in patients with severe-to-very severe stable COPD,without additional adverse effects.Therefore,it should be encouraged in clinical practice. Key words: Chronic obstructive pulmonary disease ;  Tiotropium ;  Salmeterol/fluticasone propionate

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective The purpose of the study was to investigate the effect of tiotropium combined with salmeterol/fluticasone propionate in patients with severe to-very severe stable chronic obstructive pulmonary disease (COPD).Methods One hundred and two patients admitted for severe-tovery severe stable COPD from January 2008 to February 2010 were randotnly assigned to receive tiotropium alone (group A),salmeterol/fluticasone propionate (50/500 μg) alone (group B),and combination of tiotropium and salmeterol/fluticasone propionate (group C),respectively,for 6 months.All patients were assessed at months 3 and 6 for pulmonary with ventilation function,exercise tolerance and health-related quality of life.Results At both months 3 and 6,pulmonary ventilation function,exercise tolerance,and health-related quality of life were improved in all groups compared with pretreatment values.Moreover,significantly greater improvement of the three indicators was observed in group C than in groups A and B (all P <0.05).Conclusions The combination of tiotropium and salmeterol/fluticasone propionate was superior to any single-agent treatment in improving pulmonary ventilation function,exercise tolerance,and quality of life in patients with severe-to-very severe stable COPD,without additional adverse effects.Therefore,it should be encouraged in clinical practice. Key words: Chronic obstructive pulmonary disease ;  Tiotropium ;  Salmeterol/fluticasone propionate

Key concepts: Medicine, Salmeterol, Fluticasone propionate, COPD, Fluticasone, Tiotropium bromide, Internal medicine, Pulmonary function testing

Related papers

Back to paper searchBrowse research topicsOriginal source
Effect of tiotropium combined with salmeterol/fluticasone propionate in patients with severe-to-very severe stable chronic obstructive pulmonary disease — Research Paper | ScholarLens